Reference

A stability study of clindamycin hydrochloride and phosphate salts in topical formulations

A stability study of clindamycin hydrochloride and phosphate salts in topical formulations. Migton, J. M.; Kennon, L.; Sideman, M.; Plakogiannis, F. M. (Arnold and Marie Schwartz Coll. Pharm. Health Sci., LIU, Brooklyn, NY 11201, USA). Drug Dev. Ind. Pharm., 10(4), 563-73 (English) 1984. CODEN: DDIPD8. ISSN: 0363-9045. DOCUMENT TYPE: Journal CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 22 The stability of clindamycin-HCl (I-HCl) [21462-39-5] and I phosphate [24729-96-2] was studied in topical liq. formulations prepd. with the following solvents: solvent A (70% iso-PrOH [67-63-0], 10% propylene glycol [57-55-6] and 20% water), solvent B (48% iso-PrOH, polyoxyethylene ethers, acetone [67-64-1], salicylic acid [69-72-7] and allantoin [97-59-6]), solvent C (40% EtOH [64-17-5], acetone, polysorbate 20 [9005-64-5], fragrance and water) and "std." (50% iso-PrOH, propylene glycol and water) in glass and plastic containers at 25°, 40°, and 50°. Better stability was obtained in glass containers than in plastic containers. At 25°, both the I-HCl and I phosphate formulations in solvent B showed poorer stability than in the other solvents irresp. of the type of container, while formulations in solvent C showed the best stability. In addn., the effect of the pH on the stability of the formulations was detd., and at pH values below 4, the stability of all formulations decreased.

Pharmacokinetic comparison of three clindamycin phosphate dosing schedules

Pharmacokinetic comparison of three clindamycin phosphate dosing schedules. Townsend, Raymond J.; Baker, Robert P. (Med. Inf. Unit., Upjohn Co., Kalamazoo, MI 49001, USA). Drug Intell. 24729-96-2 is the cas registry number. This chemical is also mentioned in this article. Clin. Pharm., 21(3), 279-81 (English) 1987. CODEN: DICPBB. ISSN: 0012-6578. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) In a randomized, 3-way crossover study, male volunteers received clindamycin phosphate [24729-96-2] 600 mg i.v., every 6 h (treatment A), 600 mg i.v. every 8 h (treatment B), or 900 mg i.v., every 8 h (treatment C). The results indicated that treatment C yielded higher peak plasma clindamycin concns. than treatments A or B. There were no differences in min. plasma clinadmycin concns. (Cmin) or area under the plasma concn. vs. time curve (AUC24) between treatments A and C. However, both treatments A and C yielded greater Cmin and AUC24 values than treatment B. There were no differences among treatments for clindamycin clearance. It is concluded that clindamycin phosphate at 900 mg given every 5 h is a pharmacokinetically acceptable alternative to clindamycin phosphate 600 mg given every 6 h. .